<![CDATA[Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer]]>
The treatment paradigm for patients with hormone receptor–positive, HER2-negative metastatic breast cancer is undergoing a transformative shift with the emergence of oral selective estrogen receptor degraders (SERDs), although best practices based on …